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Recent clinical studies have shown the promise of
bcl-2 antisense therapy in patients with melanoma.
To further demonstrate the importance of bcl-2 and
validate the related antiapoptotic protein bcl-xL as
targets for antisense therapy in melanoma, their
implication as survival factors in melanoma cells of
different clinical stages as well as in normal melano-
cytes was investigated. Primary cell cultures derived
from 17 melanomas, the cell line A375, and normal
melanocytes from healthy donors were treated with
antisense oligonucleotides targeting either the bcl-xL
mRNA or the bcl-2 and the bcl-xL mRNAs simul-
taneously. Bcl-2 and bcl-xL expression in cells was
analyzed by real-time polymerase chain reaction
and Western blotting. Cell viability was assessed in
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide and apoptosis assays. Bcl-2 expression was
low in melanoma cells of stages I, II, and III, hardly
detectable in A375 cells, but high in normal melano-
cytes. Bcl-xL expression was high in all cell types
tested. As shown in A375 cells and the stage III mela-
noma cells 0513, both the bcl-xL monospeci®c oligo-
nucleotide 4259 and the bcl-2/bcl-xL bispeci®c
oligonucleotide 4625 effectively reduced tumor cell
viability by induction of apoptosis with IC50 values
ranging from 200 to 350 nM. Oligonucleotide 4625
proved to be superior to 4259, as it signi®cantly
reduced the viability of cells from all melanoma
stages. Both oligonucleotides reduced also the viabil-
ity of normal melanocytes. Our data suggest that
bcl-2 and bcl-xL are promising targets for antisense
therapy of melanoma, and that the simultaneous
downregulation of their expression may provide
additional clinical bene®t. Key words: antisense/apopto-
sis/bcl-2/bcl-xL/melanoma. J Invest Dermatol 118:505±
512, 2002
A
dvanced melanoma is an aggressive disease and its
incidence is rapidly increasing (Urist and Karnell,
1994; Dummer et al, in press). In contrast to localized
melanoma, which has a good prognosis after adequate
surgery, metastatic melanoma has a poor prognosis
due to the development of drug resistance (Jansen et al, 2000). As
most chemotherapeutic agents act by induction of apoptosis
(Fisher, 1994), treatment failure has been linked to the inability
of melanoma cells to undergo apoptosis in response to cytotoxic
damage. Several lines of evidence suggest that apoptosis resistance
in melanoma relies on ineffective signaling via death receptors and
caspase-8 (Irmler et al, 1997; Grif®th et al, 1998; Thomas and
Hersey, 1998), inactivation of the apoptosis effector protein apaf-1
(Soengas et al, 2001), and deregulated expression of apoptosis
inhibitors such as bcl-2, bcl-xL, and the IAP survivin (Jansen et al,
1998; Grossman et al, 1999).
Antisense oligonucleotides are useful for target validation and
functionalization, and as therapeutic agents for the inhibition of
disease-related gene expression. Antisense oligonucleotides inhibit-
ing bcl-2 or bcl-xL expression have proven to be potent inducers of
apoptosis and valuable agents for the treatment of proliferative
disorders such as cancer (Cotter et al, 1994; Jansen et al, 1998, 2000;
Zangemeister-Wittke et al, 1998; Koty et al, 1999; Leech et al,
2000; SimoÄes-WuÈst et al, 2000). We previously demonstrated the
ability of the 2¢-O-2-methoxyethyl (2¢-MOE) modi®ed gapmer
antisense oligonucleotide 4259 targeting the bcl-xL mRNA to
induce apoptosis in lung and breast cancer cells (Leech et al, 2000;
SimoÄes-WuÈst et al, 2000). Although from a mechanistic point of
view bcl-2 and bcl-xL are functionally indistinguishable, there is
evidence in support of distinct biologic roles of these proteins in
protecting cells from apoptosis induced by different stimuli
(Simonian et al, 1997; Lee et al, 1999). This issue is further
complicated by the cellular heterogeneity of tumor tissues and the
®nding that tumor cells may switch expression from one death
antagonist to the other (Han et al, 1996). Based on the uncertainty
which of the two antiapoptotic proteins is the more important
survival factor in a tumor, the use of antisense oligonucleotides that
simultaneously inhibit bcl-2 and bcl-xL expression might be
advantageous. The 2¢-MOE gapmer antisense oligonucleotide 4625
targets a region of high homology shared by the bcl-2 and the bcl-
xL mRNAs. It is fully complementary to bcl-2 and owing to its
enhanced binding af®nity can overcome the three base mismatches
to bcl-xL. Recent studies have shown that oligonucleotide 4625
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induces apoptosis in tumor cells of various histologic origins in vitro
and has antitumor activity in vivo (Zangemeister-Wittke et al, 2000;
Gautschi et al, 2001).
The implication of bcl-2 and bcl-xL in the development and
progression of melanoma is still disputed. Although their
upregulated expression was reported in some studies (Tang et al,
1998; Leiter et al, 2000), other investigators showed that Bcl-2 and
bcl-xL expression levels do not change during tumor progression
and do not differ from expression levels found in normal
melanocytes (Cerroni et al, 1995; Plettenberg et al, 1995; Selzer
et al, 1998). In addition, various studies have demonstrated an
inverse correlation between increasing tumor stage and bcl-2
expression (Saenz-Santamaria et al, 1994; Van den Oord et al, 1994;
Ramsay et al, 1995; Tron et al, 1995; Radhi, 1999). Despite
the contradictory ®ndings about the expression and survival
function of bcl-2 in melanoma, antisense oligonucleotide G3139
(GenasenseTM) was reported to sensitize melanoma cells to the
chemotherapeutic agent dacarbazine and has shown encouraging
results in patients with refractory melanoma in a recent phase II
clinical study (Jansen et al, 1998, 2000).
In view of the promise of bcl-2 antisense therapy and to gain
further knowledge about the role of bcl-2 and bcl-xL as survival
factors for melanoma cells, we examined their expression in a
melanoma cell line, a series of primary melanoma cell cultures
derived from tumors of different clinical stages, and in normal
melanocytes. In addition, we used antisense oligonucleotides to
selectively downregulate the expression of bcl-xL, or of bcl-2 and
bcl-xL simultaneously, and investigated their ability to induce
apoptosis in the various target cells.
MATERIALS AND METHODS
Cell culture Primary melanoma cell cultures, derived from melanoma
samples as previously described (Yue et al, 1997), were cultured in
RPMI-1640 (Hyclone Europe, Cramlington, U.K.) containing 10% fetal
bovine serum (Hyclone Europe). Normal melanocytes were isolated as
previously described (Geertsen et al, 1998) from foreskin obtained from
the Children's Hospital ZuÈrich. They were cultured in medium 154
containing human melanocyte growth supplement (Cascade Biologics,
Portland, OR). Both cell culture media were supplemented with 2 mM
L-glutamine, 50 IU per ml penicillin, and 50 mg per ml streptomycin.
Cells were maintained at 37°C in a humidi®ed atmosphere containing
5% CO2.
Real-time polymerase chain reaction (PCR) Real-time PCR was
performed as described previously (Zangemeister-Wittke et al, 2000).
Brie¯y, total RNA was isolated from cells by use of the RNeasy Mini
Kit (Qiagen, Basel, Switzerland). For cDNA synthesis Taqman Reverse
Transcription Reagents were used, and for real-time PCR an ABI Prism
7700 Sequence Detection system was used (Perkin Elmer Applied
Biosystems, Foster City, CA). Relative quanti®cation of gene expression
was performed using the comparative threshold cycle method and rRNA
as an internal standard. For bcl-xL ampli®cation, primers with the
sequences 5¢-TCCTTGTCTACGCTTTCCACG-3¢ and 5¢-GGTCGC-
ATTGTGGCCTTT-3¢ were used together with a 5¢-ACAGTGCCC-
CGCCGAAGGAGA-3¢ Taqman probe. For bcl-2 ampli®cation, primers
with the sequences 5¢-CATGTGTGTGGAGAGCGTCAA-3¢ and 5¢-
GCCGGTTCAGGTACTCAGTCA-3¢ were used together with a 5¢-
CCTGGTGGACAACATCGCCCTGT-3¢ Taqman probe. The bcl-xL
and bcl-2 probes were labeled at the 5¢ end with the reporter dye
molecule 6-carboxy-¯uorescein and at the 3¢ end with the quencher dye
molecule 6-carboxy-tetramethyl-rhodamine. A BLAST search of the
NCBI database revealed no homology of the primer and probe
sequences to other known human genes. Relative data are presented in
comparison with a calibrator, which was either an untreated control
sample in the case of treatment with oligonucleotides, or tumor 0513 in
the case of basal expression levels in the various tumors.
Western blot analysis Cell lysates were subjected to Western blot
analysis as described previously (Leech et al, 2000). Brie¯y, 25 mg of
soluble protein per sample were separated on 12% polyacrylamide
sodium dodecyl sulfate gels. Transfer to polyvinylidene ¯uoride
membranes was performed in semidry blotting chambers for 1 h. The
blots were blocked in Tris-buffered saline containing 5% bovine serum
albumin and 5% nonfat milk and then incubated overnight at 4°C with
mouse antihuman bcl-2 monoclonal antibody (Dako Diagnostics,
Glostrup, Denmark), or rabbit antihuman bcl-xL antibody (Transduction
Laboratories, Lexington, KY). Actin staining with a mouse antiactin
monoclonal antibody (ICN Biomedicals, Aurora, OH) was used as a
loading control. To detect the primary antibodies, blots were incubated
with rabbit antimouse or goat antirabbit immunoglobulin peroxidase
conjugates, respectively (Sigma, St. Louis, MO) for 1 h at room
temperature. Visualization of the immunocomplexes was performed by
enhanced chemiluminescence using the ECL kit (Amersham Pharmacia
Biotech, DuÈbendorf, Switzerland), followed by exposure to X-ray ®lms.
Relative basal protein levels were quanti®ed using Scion software (Scion,
Frederick, MD) on scanned ®lms, with the b-actin level as internal
standard and the Bcl-2 and Bcl-xL protein levels in tumor 0513 as
calibrator.
Antisense oligonucleotides Antisense oligonucleotides with the
following sequences were synthesized and puri®ed as described elsewhere
(Leech et al, 2000; Zangemeister-Wittke et al, 2000; Gautschi et al,
2001): 4259, 5¢-AsAsAsGsTsAsTsCsCsCsAsGsCsCsGsCsCsGsTsT-3¢;
4258, 5¢-CsAsTsAsTsCsAsCsGsCsGsCsGsCsAsCsTsAsTsG-3¢; 4625, 5¢-
AsAsGsGsCsAsTsCsCsCsAsGsCsCsTsCsCsGsTsT-3¢; 4626, 5¢-CsAsCs-
GsTsCsAsCsGsCsGsCsGsCsAsCsTsAsTsT-3¢. The underlined nucleo-
tides are 2¢-MOE-modi®ed. Oligonucleotide 4259 is fully comple-
mentary to the bcl-xL mRNA and has three unmodi®ed mismatching
nucleotides to bcl-2. Oligonucleotide 4625 is fully complementary to the
bcl-2 mRNA and has three mismatching nucleotides to the bcl-xL
mRNA of which two are modi®ed by 2¢-MOE. Oligonucleotides 4258
and 4626 are scrambled sequence controls to oligonucleotides 4259 and
4625, respectively.
Delivery of antisense oligonucleotides to cells Oligonucleotides
were delivered to cells in the form of complexes with the transfection
reagent lipofectin (Gibco BRL, Life Technologies, Glasgow, U.K.).
Brie¯y, lipofectin 100 mg per ml was allowed to complex with
oligonucleotides (6.5 mM) in serum- and antibiotic-free RPMI, prior to
dilution and addition to cells, which had been plated the previous day in
RPMI with 10% fetal bovine serum without antibiotics. Following
various times of incubation, cells were either harvested or the
transfection mixture was replaced by fresh medium (containing fetal
bovine serum and antibiotics), and cells were further incubated at 37°C
in a humidi®ed atmosphere containing 5% CO2 until harvesting.
Measurement of cell growth Cell growth was measured by use of a
colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay as described previously (Leech et al, 2000). Brie¯y,
for each experiment 3000 cells per well were plated in 96-well plates
and incubated overnight before a 20 h transfection with oligonucleotides.
Following transfection cells were incubated for another 44 h at 37°C in
normal tissue culture medium as described above. Subsequently, 10 ml
MTT reagent (Sigma) [(10 mg per ml in phosphate-buffered saline
(PBS)] were added and allowed to react for 1.5 h at 37°C prior to the
addition of solubilization reagent (100 ml). Substrate cleavage was
monitored at 570 nm by use of a SPECTRAmax 340 microplate reader
and analyzed using the SOFTmax PRO software (Molecular Devices,
Sunnyvale, CA). Untreated cells were taken as control.
Determination of cell death Tumor cell death was determined based
on trypan blue dye uptake. Cells were incubated with 0.04% trypan blue
in PBS for 5 min at room temperature, and the percentage of dead cells
was calculated by counting the numbers of dead and viable cells using
phase contrast microscopy.
Measurement of caspase-3-like protease activity Caspase-3-like
protease activity in cells was measured by use of a colorimetric test
system. Detached and attached cells were harvested as described above,
pooled, and lyzed in buffer by freeze/thawing essentially as described
previously (Olie et al, 2000). Lysates were centrifuged at 17,500g at 4°C
for 15 min. Cytosolic protein (40 mg) was mixed with 80 mM of the
caspase-3-speci®c substrate DEVD-pNa (Bachem, DuÈbendorf,
Switzerland) and incubated at 37°C. Subsequently, substrate cleavage was
monitored at 405 nm using a SPECTRAmax 340 microplate reader and
analyzed using SOFTmax PRO software (Molecular Devices). To
con®rm that substrate cleavage was due to caspase activity, extracts were
incubated in the presence of 10 mM of the caspase-3-speci®c inhibitor
DEVD-CHO (Bachem) for 30 min at 37°C, prior to the addition of
substrate. The value (in arbitrary absorbance units) of the absorbance
signal of the inhibited sample was subtracted from that of the
noninhibited sample.
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Hoechst staining of nuclei Cells were washed with PBS and ®xed for
15 min in 5 mg per ml Hoechst 33342 (Sigma) containing 4%
paraformaldehyde. Subsequently, cells were washed three times with
PBS, centrifuged onto glass slides by cytospin centrifugation, and
mounted with Mowiol (Calbiochem, La Jolla, CA). Stained nuclei were
photographed by use of a Nikon ¯uorescence microscope (Nikon,
KuÈsnacht, Switzerland).
Statistical analysis The Student's t test was used to determine the
signi®cance of the differences between scrambled control and antisense-
treated cells.
RESULTS
bcl-2 and bcl-xL protein expression in primary cultures of
melanoma cells or normal melanocytes The expression of
bcl-2 and bcl-xL and their role as cell survival factors during
melanoma progression is disputed. We determined the expression
levels of bcl-2 and bcl-xL in 17 primary melanoma cell cultures
derived from eight primary tumors (clinical stage I), four lymph
node metastases (stage II), and ®ve distant metastases (stage III)
obtained from 13 patients and in the established melanoma cell line
A375, using real-time PCR and Western blot analysis. In addition,
normal melanocytes from seven healthy donors were analyzed for
comparison. Prior to these analyses, eight of the primary melanoma
cell cultures were examined for contamination by nonmelanoma
cells and purity was found to be more than 95%. As shown in Fig 1
and Table I, bcl-2 expression was found to be increased in some of
the stage III tumor-derived melanoma cells. In contrast to bcl-2,
bcl-xL expression was high in all tumor stages. Compared to cells
from the stage III tumor 0513, which expressed both bcl-2 and
bcl-xL, the A375 cell line showed hardly detectable levels of bcl-2
and high levels of bcl-xL (Fig 1B). Freshly isolated melanocytes
expressed levels of bcl-2 and bcl-xL similar to those found in 0513
melanoma cells (data not shown).
Downregulation of bcl-2 and bcl-xL gene expression using
antisense oligonucleotides Bcl-2 and bcl-xL are survival
factors and their downregulation in tumor cells may have
therapeutic implication. To downregulate bcl-xL expression in
melanoma cells we used the bcl-xL antisense oligonucleotide 4259,
a 2¢-MOE-modi®ed gapmer oligonucleotide that preferentially
targets the bcl-xL mRNA. In addition, the bcl-2/bcl-xL bispeci®c
2¢-MOE-modi®ed gapmer oligonucleotide 4625 was used, which
in a previous study with lung cancer cells was shown to induce
tumor cell apoptosis more effectively than a bcl-2 or bcl-xL
Figure 1. Basel expression levels of bcl-2 and bcl-xL protein in
melanoma cells and normal melanocytes. (A) Expression in primary
cultures of cells derived from melanomas of various clinical stages (see
Table I). Lane 1, melanoma 1121; lane 2, melanoma 0917; lane 3,
melanoma 0409; lane 4, melanoma 0325; lane 5, melanoma 0803; lane 6,
melanoma 0728; lane 7, melanoma 0513; lane 8, melanoma 0514; lane 9,
melanoma 0724, lane 10, melanoma 0513; lane 11, melanoma. 1008; Ctr,
small cell lung cancer cell line SW2 (known to overexpress Bcl-2 and
Bcl-xL) (Leech et al, 2000). (B) Comparison of bcl-2 and bcl-xL
expression in cells from melanoma 0513 and the established cell line
A375. Actin staining was performed to control for equal protein loading
of the blots. Protein extraction and Western blotting were performed as
described in Materials and Methods.
Table I. Characteristics of tumor samples from patients with melanoma
Patient TNM
Stagea mRNAb Proteinb
I II III bcl-2 bcl-xL bcl-2 bcl-xL No markerc
0514 T4N0M0 x ND ND 19 103 ND
0724 T1N0M0 x ND ND 18 112 0%
1122 T2N0M0 x ND ND 16 116 ND
0704 T1N0M0 x 13 92 18 112 ND
1008 T3N0M0 x 10 55 16 141 ND
0803 T3N0M0 x 11 44 18 94 ND
0728 T4N2M1 x 28 59 8 82 ND
1121d T3N0M0 x 20 108 16 109 0%
0917d T3N1M0 x 56 91 27 173 0%
0325 T2N1M0 x 12 171 21 124 ND
0822 No data x 78 61 39 77 <5%
0322d TxN1M0 x 22 81 2 62 ND
1209d TxN1M1 x 43 130 10 32 ND
0310d TxN1M1 x 21 117 11 74 0%
0513d TxN1M1 x 100 100 100 100 <5%
0409d TxN1M1 x 38 48 57 99 0%
0928 T4N2M1 x 343 111 141 101 5%
aStage I, primary tumor; stage II, lymph node metastasis; stage III, distant metastasis.
bBcl-2 and bcl-xL mRNA and protein levels are given relative to the level in 0513 cells and normalized to rRNA or actin, respectively.
cNo marker: Percentage of cells in the primary tumor cell cultures lacking melanoma marker as analyzed by staining for Melan A, Tyrosinase, gp100, Mage 1 and Mage
3, and ¯ow cytometry.
dTumors 1121 and 0917 were obtained from the same patient as were tumors 0322, 1209, and 0310, and tumors 0513 and 0409, respectively.
ND, not determined.
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monospeci®c antisense oligonucleotide (Zangemeister-Wittke et al,
2000). The ability of the two oligonucleotides to downregulate the
expression of their target genes was investigated using the
melanoma cell line A375 and primary tumor cells from the stage
III melanoma 0513.
Upon a 10 h transfection with 600 nM oligonucleotide 4259,
bcl-xL and bcl-2 levels were downregulated by 92% and 30%,
respectively. Transfection with 600 nM oligonucleotide 4625
reduced bcl-2 by 49% and bcl-xL by 81% (Fig 2A). In 0513
cells oligonucleotide 4259 downregulated bcl-xL and bcl-2 by 69%
and 47%, respectively, and oligonucleotide 4625 downregulated
bcl-2 by 74% and bcl-xL by 54% (Fig 2B). Treatment with the
control oligonucleotides 4258 and 4626 did not result in a
signi®cant reduction of bcl-2 and bcl-xL in the cells.
The unexpected ®nding that in A375 cells oligonucleotide 4625
has a stronger effect on bcl-xL than on bcl-2 despite the three
mismatches to bcl-xL might be due to the very low level of bcl-2 in
these cells. This may cause genomic DNA remaining as a
contaminant in the RNA preparation to mask the antisense effect
of 4625 on bcl-2. To test this hypothesis, we performed real-time
PCR with or without prior reverse transcription of RNA to
cDNA, both for untreated cells and cells treated with oligonucleo-
tide 4625. For untreated cells without the reverse transcription step
genomic DNA gave rise to a signal of about 40% relative to the
signal in untreated cells with the reverse transcription step. In cells
treated with oligonucleotide 4625, either with or without reverse
transcription the signal was also about 40% of the signal measured in
untreated cells with reverse transcription. This indicates that
oligonucleotide 4625 indeed completely eliminated the bcl-2
mRNA from A375 cells and that the remaining signal detected by
real-time PCR was derived from genomic DNA (Fig 3A). The
effect of contaminating genomic DNA on the real-time PCR
analysis of bcl-xL expression in A375 cells was negligible (Fig 3B).
Downregulation of bcl-2 and bcl-xL expression inhibits
melanoma cell growth Downregulation of bcl-2 and bcl-xL
has the potential to lower the apoptotic threshold in cells and
induces apoptosis directly or sensitizes cells to other apoptotic
stimuli. To investigate the effect of decreased bcl-2 and bcl-xL
expression on the growth of A375 cells and cells from the stage III
melanoma 0513, cells were analyzed in MTT assays. As shown in
Fig 4, oligonucleotides 4259 and 4625 reduced melanoma cell
growth in a dose-dependent manner with IC50 values ranging from
200 nM to 350 nM for A375 and 0513 cells, respectively. At a
concentration of 600 nM each oligonucleotide reduced the growth
of A375 cells by more than 80% (Fig 4A) and of 0513 cells by
more than 60% (Fig 4B) compared to the growth rate of the
respective untreated control cultures. The cytostatic effect of the
control oligonucleotides 4258 and 4626 was low.
Figure 2. Bcl-2 and bcl-xL mRNA expression levels in melanoma
cells upon treatment with antisense oligonucleotides. Decreased
target mRNA levels in A375 cells (A) and in primary cultures of cells
derived from melanoma 0513 (B) upon a 10 h treatment with either
lipofectin alone (Lipo) or lipofectin together with 600 nM of either
antisense oligonucleotide 4259 or 4625, or the respective control
oligonucleotide 4258 or 4626. Analysis of mRNA levels was performed
using real-time PCR as described in Materials and Methods. The depicted
expression levels are relative to the expression levels in untreated cells.
Values represent the mean 6 SEM (0513: for Lipo, 4625, 4626, n = 5;
for 4259, 4258, n = 4; A375: for all conditions, n = 5). In (A) *p
< 0.005; in (B) *p < 0.03, compared to untreated cells.
Figure 3. Contamination of mRNA samples from A375 cells with
genomic DNA and its effect on bcl-2 and bcl-xL mRNA analysis.
(A) Untreated cells of which the RNA was not reverse transcribed (U±)
and cells treated with 600 nM oligonucleotide 4625 for 10 h of which
the RNA was reverse transcribed (4625+) or not (4625±) gave a bcl-2
signal of 40% relative to the signal obtained from untreated cells of
which the RNA was reverse transcribed (U+) and the signal was set to
100%. (B) Untreated cells and cells treated with 600 nM oligonucleotide
4625 of which the RNA was not reverse transcribed to cDNA (U± and
4625±, respectively) gave a bcl-xL signal of 1% relative to the signal
obtained from untreated cells of which the RNA was reverse transcribed
(U+) and the signal was set to 100%. Cells treated with 600 nM
oligonucleotide 4625 of which the RNA was reverse transcribed to
cDNA (4625+) gave a signal relative to that observed for U+ of 14%.
The bcl-2 and bcl-xL levels for U±, 4625+, and 4625± were different
from the level obtained for untreated cells (p < 0.05). Moreover, the
bcl-xL level detected for U± and 4625± was different from the level
detected for 4625+ (*p < 0.05).
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Downregulation of bcl-2 and bcl-xL expression induces
apoptosis in melanoma cells To investigate whether the
reduction of melanoma cell growth upon antisense treatment was
due to increased cell death and apoptosis, A375 cells and 0513
melanoma cells were subjected to trypan blue exclusion analysis and
Hoechst staining of nuclei. As shown in Fig 5(A), (B), both
melanoma cell types underwent time-dependent death upon
treatment with the antisense oligonucleotides. Treatment with
600 nM oligonucleotide increased cell death by 55% to more than
75% 64 h after the start of a 20 h transfection. In A375 cells death
occurred earlier upon treatment with the bispeci®c oligonucleotide
4625 compared to treatment with the monospeci®c oligo-
nucleotide 4259. In agreement with the ®ndings in MTT assays
the control oligonucleotides 4258 and 4626 did not increase cell
death above background. To demonstrate that antisense treatment
induced apoptosis in cells, a representative experiment is shown, in
which oligonucleotides 4259 and 4625 induce nuclear
condensation and fragmentation in A375 and 0513 cells
(Fig 6A). Again, no toxicity of the control oligonucleotides was
observed. As a further proof that cell death occurred by apoptosis,
Fig 6(B) shows a 3-fold increase in caspase-3-like protease activity
in lysates from 4625 or 4259 antisense-treated A375 cells compared
to the various control cultures.
Downregulation of bcl-2 and bcl-xL expression decreases
the viability of melanoma cells of all clinical stages In view
of its ability to downregulate bcl-2 and bcl-xL expression and to
induce apoptosis in A375 cells and in cells from stage III melanoma,
the cytostatic activity of oligonucleotide 4625 was investigated
against further primary melanoma cell cultures. As measured in
MTT assays 600 nM oligonucleotide 4625 also reduced the growth
of melanoma cells of other clinical stages, although with different
ef®ciencies (Fig 7).
Downregulation of bcl-2 and bcl-xL expression inhibits the
growth of normal melanocytes Normal melanocytes also
express bcl-2 and bcl-xL and thus are likely to be equally sensitive
to the growth-inhibitory effect of bcl-2 or bcl-xL antisense therapy
as their malignant cell counterparts. As shown in Fig 8
oligonucleotides 4259 and 4625 decreased melanocyte growth in
a dose-dependent manner with an IC50 value in the range of
200 nM. At a concentration of 600 nM both oligonucleotides
decreased the growth of melanocytes by more than 80% compared
to the growth rate of untreated control cultures. Similar to the
®ndings with melanoma cells, the effects of the control
oligonucleotides 4258 and 4626 were low.
DISCUSSION
The induction of apoptosis is inhibited by two major groups of
inhibitors: the antiapoptotic members of the bcl-2 family bcl-2 and
bcl-xL, and the IAPs. Various preclinical and clinical studies have
shown that downregulation of bcl-2, bcl-xL or the IAP survivin has
therapeutic potential by inducing tumor cell apoptosis directly or
by sensitizing tumor cells to other apoptotic stimuli including DNA
damage provided by chemotherapy or growth factor withdrawal
(reviewed in Olie and Zangemeister-Wittke, 2001). Although the
role and implication of bcl-2 and bcl-xL in the development and
progression of melanoma is disputed (Saenz-Santamaria et al, 1994;
van den Oord et al, 1994; Cerroni et al, 1995; Plettenberg et al,
1995; Ramsay et al, 1995; Tron et al, 1995; Selzer et al, 1998; Tang
et al, 1998; Radhi, 1999; Leiter et al, 2000) bcl-2 antisense therapy
holds promise for patients with melanoma, especially when used in
combination with chemotherapy (Jansen et al, 1998, 2000).
To further unveil the importance of bcl-2 and bcl-xL as survival
factors for melanoma cells, we analyzed their expression levels in a
series of primary melanoma cell cultures derived from primary
tumors (clinical stage I), lymph node metastases (stage II), or distant
metastasis (stage III), as well as in the established melanoma cell line
A375 and in normal melanocytes from healthy donors. Cells in
primary melanoma cultures generally expressed low levels of bcl-2,
whereas in the A375 cell line bcl-2 expression was hardly
detectable. In contrast, bcl-2 was high in normal melanoyctes as
well as in some cell cultures from distant metastases. bcl-xL was
high in all melanoma cell cultures and in normal melanocytes.
Based on these ®ndings it is rather unlikely that overexpression of
the antiapoptotic proteins bcl-2 and bcl-xL plays a causal role in the
development of melanoma. More investigations including those
addressing the expression of other anti- and pro-apoptotic proteins
in melanoma cells of different stages are required, before conclu-
Figure 4. Growth of A375 melanoma cells and of primary cell cultures from melanoma 0513 upon treatment with antisense
oligonucleotides. (A) A375 melanoma cells; (B) primary cell cultures from melanoma 0513. Cells were treated for 20 h with either lipofectin alone
(Lipo) or lipofectin together with oligonucleotide 4259 or 4258 (upper panel) and 4625 or 4626 (lower panel). Transfection was followed by medium
change and subsequent incubation for 44 h prior to analysis. Cell growth was measured in MTT assays as described in Materials and Methods. The
depicted viability is relative to the viability of the respective untreated cells. Values represent the mean 6 SD (A375, n = 4; 0513, n = 2). In (A) *p
< 0.05 when comparing the effect of antisense with the effect of scrambled control oligonucleotide at all concentrations, except for 4259 and 4258 at
75 nM. In (B) *p < 0.05 and p < 0.03 when comparing the effect of 4259±4258 and 4625±4626, respectively, at 600 nM.
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sions regarding possible changes of the apoptotic threshold during
melanomagenesis can be drawn.
In view of the promising results achieved with bcl-2 antisense
therapy in patients with melanoma, the low level of bcl-2 found
especially during earlier tumor stages is surprising. Possibly, in these
cells minute amounts of this protein are mandatory to keep the
intrinsic death signaling by pro-apoptotic bcl-2 family members in
check. Similar to these early stage melanoma cells, non-small-cell
lung cancer cells, which also express low levels of bcl-2 and high
levels of bcl-xL, are more sensitive to apoptosis induction by
downregulation of bcl-2 and bcl-xL together instead of bcl-xL
alone (Leech et al, 2000). Bcl-xL was more prominently expressed
than bcl-2 in tumors of all clinical stages, suggesting that this
antiapoptotic protein is at least as indispensable for melanoma
growth and development as bcl-2 and may represent an even more
attractive target for antisense therapy. In those cases in which both
proteins appear to be valid targets for antisense therapy, we think
that the simultaneous downregulation of both targets with a single
antisense molecule represents a promising therapeutic option. To
test this hypothesis, the ability of two different antisense
oligonucleotides to induce apoptosis in melanoma cells of different
clinical stages was investigated. The 2¢-MOE-modi®ed gapmer
oligonucleotide 4259 preferentially downregulates bcl-xL expres-
sion, and the bispeci®c 2¢-MOE-modi®ed gapmer oligonucleotide
4625 simultaneously downregulates bcl-2 and bcl-xL expression.
The strong pro-apoptotic effect of 4625 on small cell lung cancer
cells, which were found to be resistant to 4259 despite the
coexpression of both survival factors (Zangemeister-Wittke et al,
2000), suggests that the simultaneous downregulation of bcl-2 and
bcl-xL might be advantageous compared to a monospeci®c
antisense treatment. As expected oligonucleotide 4625 effectively
downregulated bcl-2 and bcl-xL expression also in the different
Figure 5. Viability of A375 cells and of primary cell cultures from
melanoma 0513 upon treatment with antisense oligonucleotides.
(A) A375 cells; (B) primary cell cultures from melanoma 0513. Cells
remained untreated or were treated for 20 h with either lipofectin alone
(Lipo) or lipofectin together with oligonucleotide 4259, 4258, 4625, or
4258. Transfection was followed either by harvesting and analysis or by
medium change and subsequent incubation for 20 h or 44 h prior to
analysis. Cell death was assessed based on trypan blue exclusion as
described in Materials and Methods. Values represent the mean 6 SD
(A375, n = 4; 0513, n = 5); *p < 0.04.
Figure 6. Induction of apoptosis in A375 cells upon treatment
with antisense oligonucleotide. (A) Hoechst staining of nuclei
displaying chromatin condensation and fragmentation in A375 cells and
in cultures of cells from melanoma 0513 64 h after the start of a 20 h
transfection with 600 nM antisense oligonucleotide 4259 or 4625. Cells
similarly treated with control oligonucleotide 4626 or 4258 did not
reveal signs of apoptosis. Nuclei were stained and photographed as
described in Materials and Methods. (B) Caspase activity in lysates of A375
cells upon treatment with antisense oligonucleotides. Cells remained
untreated or were treated for 20 h with either lipofectin alone (Lipo) or
lipofectin together with oligonucleotide 4259, 4258, 4625, or 4626.
Transfection was followed by medium change and subsequent incubation
for a further 20 h prior to analysis. Protease activity was measured as
described in Materials and Methods. Results from a representative
experiment (n = 3) are shown.
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melanoma cells, whereas 4259 showed preferential activity against
bcl-xL. In A375 cells expressing barely detectable levels of bcl-2,
the cytotoxic effects of 4259 and 4625 were similar, indicating that
the downregulation of bcl-xL alone suf®ced to induce apoptosis. In
0513 cells expressing both bcl-xL and bcl-2, oligonucleotide 4625
was slightly more effective than 4259 and the induction of apoptosis
occurred earlier. This suggests an additional cytoprotective function
provided by the bcl-2 protein in these cells. Considering the
application of antisense therapy for advanced and heterogeneous
malignancies with varying bcl-2 and bcl-xL levels, the superiority
of the bispeci®c oligonucleotide 4625 becomes obvious. Bcl-2 and
bcl-xL differ in their ability to protect cells from apoptosis induced
by different endogenous and exogenous stimuli (Simonian et al,
1997; Lee et al, 1999). Thus, it is likely that bcl-2/bcl-xL bispeci®c
antisense therapy not only targets a broader spectrum of tumor
cells, but also sensitizes tumor cells to a broader spectrum of
chemotherapeutic agents compared to a bcl-2 or bcl-xL mono-
speci®c therapy.
The hope that antisense strategies targeting genes involved in the
inhibition of apoptosis offer a reasonable therapeutic index is based
on the expectation that tumor cells have a higher rate of intrinsic
death signaling due to their high level of genetic instability. Thus,
tumor cells more strongly rely on the overexpression of
antiapoptotic proteins for survival. This concept of selectivity by
differential sensitivity, however, seems not to hold true for all
tissues and cells in the body. We found that normal melanocytes
also rely on the survival function of bcl-2 and bcl-xL, as they also
underwent apoptosis upon treatment with the bcl-xL or bcl-2/bcl-
xL bispeci®c antisense oligonucleotides. Melanocyte apoptosis also
occurs in bcl-2 ±/± mice and is observed in melanoma patients
treated with vaccination immunotherapy against melanoma-
speci®c antigens as well as upon immune recognition of melanocyte
differentiation antigens resulting in autoimmune depigmentation
(Nestle et al, 1998; Overwijk and Restifo, 2000). Severe clinical
side-effects related to the transient downregulation of bcl-2 in
normal melanocytes and other normal tissues, however, have not
been reported so far.
Our data suggest that both bcl-2 and bcl-xL are important
survival factors for melanoma cells, and that their expression is
differentially regulated during the different clinical stages. In view
of the promising clinical results achieved with bcl-2 antisense
therapy and the consistent high and prominent expression of bcl-xL
in melanoma cells, the use of antisense oligonucleotide 4625, which
simultaneously downregulates bcl-2 and bcl-xL expression, de-
serves attention to further improve the treatment options for
melanoma.
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